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Abstract: Quetiapine was developed in 1985 by scientists at AstraZeneca (formerly Zeneca) 
Pharmaceuticals. It received ofﬁ  cial US Food and Drug Administration approval in September 
1997 and approval in Germany in 2000. Since then, quetiapine has been used in the treatment of 
severe mental illness in approximately 70 countries including Canada, most Western European 
countries, and Japan. Quetiapine is a dibenzothiazepine derivative with a relatively broad recep-
tor binding proﬁ  le. It has major afﬁ  nity to cerebral serotonergic (5HT2A), histaminergic (H1), 
and dopaminergic D1 and D2 receptors, moderate afﬁ  nity to α1- und α2-adrenergic receptors, 
and minor afﬁ  nity to muscarinergic M1 receptors; it demonstrates a substantial selectivity for 
the limbic system. This receptor occupancy proﬁ  le with relatively higher afﬁ  nity for the 5HT2A 
receptor compared with the D2 receptor is in part responsible for the antipsychotic characteristics 
and low incidence of extrapyramidal side-effects of quetiapine. The efﬁ  cacy of quetiapine in 
reducing positive and negative symptoms of schizophrenia has been proven in several clinical 
trials with placebo-controlled comparators. Quetiapine has also demonstrated robust efﬁ  cacy 
for treatment of cognitive, anxious-depressive, and aggressive symptoms in schizophrenia. 
Long-term trials show sustained tolerability for a broad spectrum of symptoms. Quetiapine has 
also proven efﬁ  cacy and tolerability in the treatment of moderate to severe manic episodes, and 
in the treatment of juveniles with oppositional-deﬁ  ant or conduct disorders, and in the geriatric 
dementia population. Recent data indicate that quetiapine may also be effective in the treatment 
of bipolar depressive symptoms without increasing the risk of triggering manic episodes, and 
in borderline personality disorder. In comparison with other antipsychotics, quetiapine has a 
favorable side-effect proﬁ  le. In clinical trials only small insigniﬁ  cant prolongations of the QT 
interval were observed. Weight-gain liabilities and new-onset metabolic side-effects occupy 
a middle-ground among newer antipsychotics. As a result of its good efﬁ  cacy and tolerability 
proﬁ  le quetiapine has become well established in the treatment of schizophrenia and manic 
episodes. 
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Introduction
The discovery of the ﬁ  rst antipsychotics such as chlorpromazine led to a signiﬁ  cant 
change in the treatment of schizophrenia, especially with respect to “positive” symp-
toms of schizophrenia. However, it soon became obvious that this efﬁ  cacy came at 
the price of high incidence for extrapyramidal symptoms such as parkinsonism, dys-
kinesia, or dystonia; and akathisia (Nemeroff et al 2002). Additionally, conventional 
antipsychotics seem to be less effective in the treatment of “negative” symptoms 
characterized by anergia, avolition, alogia, or affective ﬂ  attening. 
The ﬁ  rst “atypical”, antipsychotic, clozapine, became available in the 1960s. While 
efﬁ  cacy on both positive and negative symptoms of schizophrenia was comparably 
better than that of the previously available antipsychotics, in 1%–2% of cases severe 
agranulocytosis developed; consequently clozapine had to be removed from the market Neuropsychiatric Disease and Treatment 2007:3(2) 220
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in 1975. Only the standard use of expensive continuous he-
matologic monitoring allowed for readmission to the market 
in 1990 with the indication to ameliorate the most treatment-
resistent schizophrenia (Nemeroff et al 2002).
A variety of “new” atypical antipsychotics have since 
been developed, to meet requirements for better tolerability 
and comparable efﬁ  cacy. While older agents still have a 
place in the treatment of schizophrenia symptomatology 
(Ganguli and Strassnig 2006), newer agents have been 
the mainstay of treatment. Quetiapine was synthesized at 
AstraZeneca (formerly Zeneca) in 1985 (Lieberman et al 
2002). Company scientists combined perlapin and ﬂ  uperlapin, 
two benzodiazepine-derived components with structural 
analogy to clozapine, but with molecular discrepancies 
explaining the lack of agranulocytosis risk (Nemeroff et al 
2002). Quetiapine was approved in September 1997 by the 
US Food and Drug Administration (FDA) and has since been 
introduced in Canada, most Western European countries, Japan 
as well as in 70 other countries worldwide for the treatment 
of schizophrenia and other psychiatric illnesses (Nemeroff 
et al 2002).
Pharmaceutical formulation
Quetiapine is available in 25, 100, 200, and 300 mg ﬁ  lm-coated 
tablets. Due to a relatively short half-life of 7 hours, quetipaine 
should be administered in 2 daily doses. The following initial 
titration schedule for schizophrenic patients should be adhered 
to: 1st day 50 mg, 2nd day 100 mg, 3rd day 200 mg, and 4th 
day 300 mg. After that, the dose may be gradually raised fur-
ther up to 750 mg per day, the recommended high dose. In the 
treatment of manic episodes in bipolar disorder the following 
titration schedule is recommended: 1st day 100 mg, 2nd day 
200 mg, 3rd day 300 mg, and 4th day 400 mg. Further dose 
adjustments up to 800 mg at day 6 should not be conducted in 
steps greater than 200 mg per day. It should be noted, however, 
that clinical experience may justify titration up to 1600 mg per 
day in selected cases (Nagy 2003). 
Indication
Quetiapine is approved for the treatment of schizophrenia and 
moderate to severe acute manic episodes. No long-term trial 
data are available yet to conﬁ  rm efﬁ  cacy on the prevention 
of manic or depressive episodes. 
Mechanisms of action
Quetiapine is a dibenzothiazepin-derivate (Nemeroff 2002) 
with a relative broad receptor afﬁ  nity proﬁ  le. Its relatively 
higher afﬁ  nity to serotonergic (5HT2A)- than to dopaminer-
gic D1- and D2-receptors (Bandelow and Ruther 2000) has 
been hypothesized to be responsible for the antipsychotic 
characteristics and the relatively low risk for extrapyramidal 
side-effects. Quetiapine also has high afﬁ  nity to histaminer-
gic and alpha-1 adrenergic receptors with a lower afﬁ  nity to 
alpha-2-adrenergic receptors, but no appreciable afﬁ  nity to 
muscarinergic acetylcholine- or GABA receptors (Table 1) 
(Richelson and Souder 2000).
Dopamine receptors
Clinical studies have shown that quetiapine has lower afﬁ  nity 
to dopaminergic D2-receptors than other comparable antipsy-
chotics. PET studies (positron emmission tomography) show 
regional differences in CNS receptor afﬁ  nity. Secondary to 
low afﬁ  nity for the dopaminergic D2-receptor, the receptor 
binding curve shows an early peak with a rapid reduction 
in receptor occupancy. This relatively low D2-receptor 
occupancy could be an explanation for the low incidence of 
extrapyramidal symptoms and only mild prolactin elevations 
(Kapur et al 2000). 
A preclinical study comparing effects of the atypical 
antipsychotics quetiapine, olanzapine and risperidone on 
CNS dopamine-receptor-density in rodents showed that after 
a 28-day treatment period, olanzapine and risperidone, but 
not quetiapine, signiﬁ  cantly increased D2-receptor binding 
throughout different cortex areas including caudate, putamen, 
nucleus accumbens, and hippocampus. Moreover, dopamine 
D4-receptor density increased during treatment with olan-
zapine or risperidone. D1- and D3-receptor density remained 
unchanged in all investigated areas (Tarazi et al 2001).
Gefvert et al (2001) studied the relationship between 
different quetiapine dosages and the D2- and 5HT2A-receptor 
occupancy by PET scans in a small sample of 5 patients. 
Dosed clinically, quetiapine showed only a relatively low 
D2-receptor occupancy, leading the authors to conclude that 
Table 1 In vitro receptor binding proﬁ  le of quetiapine (derived 
from data of Richelson and Souder 2000)
Receptor Mean  Kda (nM)
α1-adrenergic 8.1
α2-adrenergic 80
Dopamine D2  770
HistamineH1 19
Muscarinergic 1400
5HT1A 300
5HT2D 560
5HT2A 31
5HT2C  3500
aA lower Kd value indicates higher receptor afﬁ  nity.Neuropsychiatric Disease and Treatment 2007:3(2) 221
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lack of extrapyramidal symptoms during the treatment phase 
were secondary to this low occupancy (Gefvert et al 2001). 
Serotonin receptors
Quetiapine, in line with other “atypical” antipsychotics, 
exhibits a higher afﬁ  nity for 5HT2A-receptors than conven-
tional compounds (Gefvert et al 2001). Thus, quetiapine 
can partially balance disadvantages of a relatively moderate 
dopamine receptor blockade and effect a reduction in extra-
pyramidal symptoms, have good efﬁ  cacy in improving nega-
tive symptoms, and have insigniﬁ  cant prolactin elevation, all 
distinct therapeutic improvements (Stahl 2005).
Whereas a 5HT2A-receptor-blockade is opposed to an 
increased D2 antagonism, especially in nigrostriatal, meso-
cortical, and tuberoinfundibular cortex areals, it is assumed 
that the same mechanism cannot abolish a desired D2-receptor 
blockade in the mesolimbic system (Stahl 2005).
Effects on other neurotransmitters
Relatively strong afﬁ  nity to histaminergic and α1-adrenergic 
receptors may cause side-effects such as somnolence, stupor, 
dry mouth, asthenia, constipation, tachycardia, orthostatic 
hypotension, and dyspepsia. A case of quetiapine-associated 
malignant neuroleptic syndrome has been reported.
Pharmacokinetics
After oral intake quetiapine is rapidly absorbed; the main site 
of metabolism is the liver. Peak plasma levels are reached 
after approximately 1–2 hours, and half-life is 7 hours. 
Bioavailability of quetiapine is not signiﬁ  cantly affected by 
simultaneous ingestion of food (Goldstein 1999). Plasma lev-
els and dosage follow a nearly linear gradient (DeVane and 
Nemeroff 2001). Pharmakokinetic data seem to be unaffected 
by gender, ethnicity, body weight, or nicotine consumption; 
no difference between adolescents and adults has been de-
tected (McConville et al 2000). The CYP3A4 isoenzyme of 
the liver cytochrome P450 system is mainly responsible for 
quetiapine metabolism; in vitro examinations have revealed 
that CYP2D6 may also be significanlty involved (Lin 
et al 2004). In declining order, CYP3A7 (11.8%), CYP3A5 
(8.7%), and CYP2C19 (4.5%) also contribute (Lin et al 
2004). Thus far, 11 metabolites have been identiﬁ  ed, among 
which only 2 show intrinsic receptor activity (7-hydroxy-
quetiapine and 7-hydroxy-N-dealkyl-quetiapine). Quetiapine 
sulfoxide represents the quantitatively largest proportion of 
inactive metabolites (Li et al 2004). Ongoing research is in-
vestigating the pharmacologic potential of these metabolites. 
Seventy-three per cent of radio-ligand tagged quetiapine is 
excreted by the kindneys, and 21% through bowel (DeVane 
and Nemeroff 2001). 
In several clinical subpopulations, dose adjustments may 
be warranted. Geriatric patients, for example, show a reduction 
in plasma clearance by 30%–50%; the quetiapine target dose 
should thus be reduced by an equal proportion (Thyrum et al 
2000). Patients with decreased kidney function (creatinine 
clearance <30 mL/min/1.73 m²) show approximately a 25% 
reduction in plasma clearance. Patients with reduced liver 
function show an approximately 25% reduction in plasma 
clearance. A dose reduction may be indicated in these cases.
Interaction potential
Quetiapine neither inhibits nor induces known liver CYP-450 
isoenzymes. Other medications with activity on the P450 sys-
tem may however alter quetiapine plasma levels. For example, 
potent inhibitors of the CYP3A4-system, such as erythromycin 
(Li et al 2005), may elevate quetiapine plasma levels, and 
inductors including carbamazepine and phenytoin (DeVane 
and Nemeroff 2001) may reduce quetiapine levels. 
Potential medication interactions have been examined 
in various clinical studies. Concurrent administration of 
the CYP2D6-inhibitors imipramine and ﬂ  uoxetine did 
not significantly alter quetiapine metabolism (Potkin 
et al 2002a). Concurrent administration of haloperidol or 
risperidone (Potkin et al 2002b), cimetidine (Strakowksi 
et al 2002), lithium, and sodium valproate (Potkin et al 1997) 
does not change quetiapine metabolism. Thioridazine lowers 
quetiapine plasma levels and requires increase in quetiapine 
dose (Potkin et al 2002b). Interactions between quetiapine 
and cardiovascular drugs have not been studied.
Clinical efﬁ  cacy trials
Overview
Short- and long-term efﬁ  cacy has been established through 
several double-blind, placebo-controlled trials. There are also 
indications that quetiapine may be efﬁ  cacious in the treatment 
N
N
O
OH
S
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of a variety of disorders apart from schizophrenia, such as 
bipolar disorders, dementia, and in child and adolescent 
psychiatry. Economic aspects of quetiapine treatment have 
been investigated; efﬁ  cacy for treatment of aggression and 
agitation during acute schizophrenic episodes, and efﬁ  cacy in 
the treatment of iatrogenically induced psychotic symptoms 
in Parkinson’s patients has been proven.
Recent short-term trials
Efﬁ  cacy
Efficacy of quetiapine was shown in 6- to 16-week 
double-blind, placebo-controlled and in comparative 
studies. Usual psychometric instruments employed to 
establish efficacy on positive and negative symptoms of 
schizophrenia are the 
1.  Positive And Negative Syndrome Scale (PANSS; Kay 
et al 1987),
2.  Its derivative BPRS (Brief Psychiatric Rating Scale; 
Overall and Gorham 1962), and the 
3.  SAPS/SANS (Scale for the Assessment of Positive/Nega-
tive Symptoms; Andreasen 1982). 
Buckley et al (2004a) published a small meta-analysis 
of 3 placebo-controlled trials and reported equal efﬁ  cacy of 
quetiapine compared with haloperidol, chlorpromazine, and 
risperidone in the treatment of positive and negative symp-
toms, mood symptoms, and aggression, agitation, and irrita-
bility in schizophrenia patients. Quetiapine dosed at 400 mg 
showed better efﬁ  cacy, especially in the treatment of positive 
symptoms, than at lower doses (Buckley 2004a). Conversely, 
Potkin et al (2006), referring to results from another blinded, 
placebo-controlled, randomized controlled trial (RCT), found 
superior efﬁ  cacy of risperidone to quetiapine and placebo in 
all measured domains during a 2-week monotherapy phase; 
their sample consisted of acutely exacerbated DSM-IV 
schizophrenia patients requiring inpatient hospitalization. 
However, no signiﬁ  cant differences in efﬁ  cacy between both 
atypical antipsychotic treatment groups were seen during the 
following additive therapy phase.
Another meta-analysis by Schulz et al (2003) looked at 
3 placebo-controlled and 5 comparative studies of quetiap-
ine with haloperidol and found signiﬁ  cantly better efﬁ  cacy 
(p < 0.05) as compared to placebo and equal efﬁ  cacy to 
haloperidol (Schulz et al 2003). 
Sacchetti et al (2004) reported equal short-term efﬁ  cacy 
of qetiapine, olanzapine, and risperidone; and recommended 
all three medications as ﬁ  rst-line treatments in acute schizo-
phrenia (Figure 2). 
In a recently published meta-analysis Tandon and Jib-
son (2005) came to a similar conclusion. They reviewed 
published short-term, RCTs of first-line atypical antipsy-
chotics (risperidone, olanzapine, quetiapine, ziprasidone, 
and aripiprazole) in the treatment of schizophrenia and 
schizoaffective-disorder that used the PANSS to assess 
efficacy and found similar improvements among all first-
line atypical antipsychotics for all efficacy parameters 
considered.
Small et al (2002), in a 6-week study examining quetiap-
ine dose-response relationships, found signiﬁ  cantly better 
efﬁ  cacy on positive, negative, and affective symptoms for 
higher than lower doses. An initial target dose of 400 mg was 
recommended, and higher dosing according to individual 
requirements and tolerability was suggested (Small et al 
2002; Figure 3).
Some evidence for better efﬁ  cacy of atypical antipsychot-
ics in the treatment of negative symptoms of schizophre-
nia exists (Möller 1999). A meta-analysis of 4 RCTs by 
Tandon (2004) containing data on 1106 patients explored 
quetiapine’s direct effects on schizophrenic negative symp-
toms. Treatment effected a signiﬁ  cantly greater improve-
ment in SANS-scores in the quetiapine group compared 
with placebo (p < 0.001). A direct effect of quetiapine on 
schizophrenic negative symptoms was suggested, since 
indirect contributors such as antidepressant effects or lack 
of extrapyramidal-motor side-effects (EPS) were statisti-
cally excluded (Figure 4). 
A 12-week RCT (quetiapine, n = 22; risperidone, n = 22) 
by Riedel et al (2005) showed equal efﬁ  cacy in the treatment 
of negative symptoms of schizophrenia with quetiapine 
tending to improve the SANS-“Alogia” subscale to a greater 
extent (Figure 5).
Zhong et al (2006) reported results from a 8-week ran-
domized, double-blind, ﬁ  xed-dose trial comparing quetiapine 
and rsiperidone in the treatment of schizophrenia. Patients 
(n = 338 quetiapine, mean dose 525 mg; risperidone n = 335, 
mean dose 5.2 mg) were evaluated with the Positive and 
Negative Syndrome Scale (PANSS) and the Clinical Global 
Impression Scale (CGI). Improvements with both treatments 
were comparable on PANSS total, negative, and general 
psychopathology subscale, Risperidone-treated patients had 
a signiﬁ  cantly greater (p = 0.03) improvement on positive 
subscores. EPS were significantly more frequent with 
risperidone treatment (n = 22) than with quetiapine (n = 13; 
p = 0.01). Somnolence was more common with quetiapine 
(26%) than risperidone (20%; p = 0.04). The authors conclude 
that both agents improved the patients’ symptomatolgy, with Neuropsychiatric Disease and Treatment 2007:3(2) 223
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advantages for risperidone in efﬁ  cacy and for quetiapine in 
tolerability.
Short-term efﬁ  cacy on agitation/
aggression
Nasrallah et al (2002) showed in a meta-analysis better 
efficacy of quetiapine than placebo and haloperidol on 
aggression and agitation. Aggression and agitation were 
estimated via the BPRS hostility-cluster subscore (items 
“anxiety”, “tension”, “hostility”, “suspiciousness”, “unco-
operativeness”, and “excitement”).
A 6-week double-blind placebo-controlled trial by 
Chengappa et al (2003) compared the efﬁ  cacy of quetiapine 
versus haloperidol on hostility, agitation, and aggression 
in a total of 257 patients (quetiapine, n = 175; haloperidol, 
n = 42, placebo, n = 40). Main outcome measure was the 
observed change in BPRS scores. A clear beneﬁ  t of que-
tiapine in the treatment of all three symptoms was shown. 
Path analysis revealed direct effects of quetiapine on these 
symptoms independent of a more general improvement of 
psychopathology. 
A naturalistic open-label pilot study with 36 acutely 
psychotic patients by Ganesan et al (2005) showed good 
applicability of quetiapine; after the ﬁ  rst treatment day, 
improvements in BPRS scores and the Overt Aggression 
Scale (OAS), especially on the item “aggression against oth-
ers” was observed. Mean doses of quetiapine administered 
on Days 1, 2, 3, 4, and 5 were 203, 276, 351, 373, and 384 
mg/day, respectively. The authors urged further examina-
tion of quetiapine’s efﬁ  cacy in treating acute agitation and 
aggression through RCTs.
A beneﬁ  cial effect of a treatement with quetiapine on 
aggression, anxiety, and hostility could also have been sup-
ported by the CATIE study in which quetiapine exhibited 
a comparable sedative effect as olanzapine (Lieberman 
et al 2005).
Short-term efﬁ  cacy in depression/anxiety 
Quetiapine’s efﬁ  cacy in the treatment of schizophrenia-
related depressive symptoms has been established by several 
studies. Meltzer and Lee (2001) conducted 2 comparative 
analyses: 4 randomized-double blind 6- to 12-week trials 
Figure 2 Positive and Negative Syndrome Scale (PANSS) total score changes from baseline (mean values: 103.5, 98.5, and 96.0 for quetiapine-, olanzapine-, and risperidone-
treated patients) (compiled from data of Sacchetti et al 2004).
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(quetiapine, n = 676; haloperidol, n = 559) and 3 randomized, 
placebo-controlled, double-blind, 6-week trials (quetiapine, 
n = 284; placebo, n = 116). Treatment with quetiapine 
was signiﬁ  cantly superior to haloperidol on BPRS factor I 
(“somatic concern”, “anxiety”, “guilt feelings”, “depressive 
mood”) and Kay´s “Depressive Factor” (sum of PANSS-
items: “anxiety”, “guilt feelings”, “depression”, “somatic 
concern”, and “preoccupation”). In the placebo-controlled 
trials, quetiapine was signiﬁ  cantly superior to placebo in 
improving the BPRS-mood cluster and BPRS factor I.
A double-blind, randomized, multi-center trial analyzed 
by Emsley et al (2003) compared the efﬁ  cacy of quetiapine 
(600 mg/day) and high doses of haloperidol (20 mg/day) 
in partially remitted schizophrenia patients. Depressive 
symptoms were estimated with a change in the Positive 
and Negative Syndrome Scale depression factor score from 
baseline to endpoint. Quetiapine was reported to be superior 
to haloperidol in treating depressive symptoms. The path 
analyses indicated that this was a direct effect on depressive 
symptoms, and it was concluded that there is evidence for 
an antidepressant effect of quetiapine in schizophrenia and 
that its use is not limited to psychotic patients.
Short-term efﬁ  cacy in treatment-resistant 
patients
There is an approximate rate of 10%–30% of partial treatment 
resistance in schizophrenia. More efﬁ  cacious treatment for 
this subgroup is especially important. A post-hoc subanalysis 
of a trial by Emsley et al (2001) on efﬁ  cacy and tolerability 
of quetiapine compared with high-dose haloperidol revealed 
a signiﬁ  cantly better response to treatment with quetiapine 
than the comparator (response deﬁ  ned as CGI-Score ≤3; 51% 
vs 25%; p = 0.023) in previously non-responsive patients to a 
4-week treatment course with ﬂ  uphenazine (Guy et al 1970). 
According to the authors, the results may be interpreted in 
context of a better tolerability of quetiapine; they conclude 
that a switch to quetiapine may be a beneﬁ  cal option when 
faced with acute treatment-resistant schizophrenia symptom-
atology (Buckley et al 2004b).
Current long-term trials
Efﬁ  cacy
A small 2-phase open-label trial by Nagy (2003) incorporat-
ing 25 schizophrenics investigated efﬁ  cacy and tolerability 
Figure 3 Percentage of patients responding to higher (mean 439 mg/d) and lower (mean 229 mg/day) quetiapine doses, and placebo (compiled from data of Small et al 2002).
Note: patients receiving <150 mg/d of quetiapine were not analyzed. 
•p < 0.05, quetiapine: higher vs lower dose; **p < 0.01, quetiapine: higher dose vs placebo; a≥40% reduction in Brief Psychiatric Rating Scale (BPRS) total score.
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Figure 5 Mean change in Scale for the Assessment of Positive/Negative Symptoms (SANS) scores from baseline to week 12 following treatment with quetiapine 
or risperidone.
**p < 0.01 vs baseline, ***p < 0.001 vs, baseline (paired t-tests), †p = 0.065 vs risperidone (unpaired t-test).
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Figure 4 Quetiapine signiﬁ  cantly improved negative symptoms in a pooled analysis of three double-blind randomized controlled trials within 3 weeks (compiled from data 
of Tandon 2004).
*p < 0.05, **p < 0.01 vs placebo.
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over 16 months of treatment. The trial consisted of a ﬁ  rst 
phase, a 4-week trial, which examined quetiapine’s efﬁ  cacy 
in relatively high doses, up to 1600 mg daily, and an ensu-
ing second phase, a 15-month relapse prevention part, with 
dose reduction to an average of 600 mg/day. Good short-
term efﬁ  cacy and tolerability of the high initial doses was 
reported; the relapse-prevention part was well tolerated as 
well. Neither EPS including akathisia nor signiﬁ  cant weight 
gain was observed.
Buckley (2004b) reported results of a subanalysis of three 
pooled double-blind randomized trials (n = 259), incorporat-
ing robust responders to 6-week quetiapine administration 
who were subsequently observed further for a total of 156 
weeks. More than half of the patients sustained their initial 
6-week treatment response and some improved further.
A 16-week, randomized, multicenter, double-blind trial 
reported by Mullen et al (2001; n = 728) compared the efﬁ  cacy 
of quetiapine and risperidone in the treatment of outpatients 
with schizophrenia and related disorders. Both drugs were 
found to be similar in efﬁ  cacy but quetiapine showed a nu-
merically but not statistically superior efﬁ  cacy in ameliorating 
depressive symptoms while retaining good tolerability. 
Kasper et al (2004) published a pooled data analysis of 
674 patients from 4 long-term, open-label, extension phase 
IIIa trials. The authors argue that quetiapine therapy (mean 
dose 472.4 mg) over 208 weeks successfully treated positive 
and negative BPRS symptoms, CGI, and SANS scores. This 
led the authors to conclude that quetiapine is efﬁ  cacious in 
long-term relapse prevention of schizophrenia (Figure 6).
In a large-scale, double-blind trial comparing multiple atypi-
cal antipsychotics against perphenazine (Clinical Antipsychotic 
Trials of Intervention Effectiveness [CATIE]) (Lieberman 
et al 2005), the efﬁ  cacy of treatment was determined by means 
of discontinuation of treatment. It demonstrated that the time 
to the discontinuation of treatment for any cause was signiﬁ  -
cantly longer in the olanzapine group than in the quetiapine 
or risperidone group. However, in this study olanzapine was 
administered above the recommended upper limit.
Cochrane meta-analysis
According to a meta-analysis looking at quetiapine for the 
treatment of schizophrenia, Srisurrapanont et al (2004) 
concluded that quetiapine is efﬁ  cacious in ameliorating 
acute psychotic exacerbations. No differences in short-term 
Figure 6 Mean changes in the Brief Psychiatric Rating Scale (BPRS) total score, Positive and Negative Symptom Cluster Score from baseline (compiled from data of Kasper et al 2004). 
p < 0.001: Changes from baseline in total, positive, and negative symptom scores at all timepoints except week 4 (total score; p < 0.01).
SD, standard deviation.
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efﬁ  cacy and overall tolerability between quetiapine and either 
conventional antipsychotics or risperidone were reported. 
Quetiapine was associated with lower short-term risk for 
EPS, but higher risk for dizziness, asthenia, and dry mouth. 
The authors conclude that while short-term tolerability and 
efﬁ  cacy are established, further pragmatic, randomized, 
comparative trials covering topics such as “usual clinical 
practice”, “mid-” and “long-term efﬁ  cacy”, “cost-beneﬁ  t 
analysis”, and “quality of life” are warranted, as these aspects 
have not been examined sufﬁ  ciently.
Long-term efﬁ  cacy on depressive 
and anxiety symptoms
A pooled analysis of three randomized, open-label, extension 
phase trials (n = 415) published by Kasper (2004) revealed 
good long-term efﬁ  cacy of quetiapine in the treatment of 
depressive and anxiety symptoms in schizophrenia patients. 
The BPRS-Cluster I (“somatic concern”, “anxiety”, “guilt 
feelings”, “depression) was used as a proxy measure.
Other indications than schizophrenia 
core symptoms
Cognition
Cognitive deﬁ  cits such as executive function, attention, work-
ing and verbal memory, visual memory, reaction time, and 
vigilance are important characteristics of the schizophrenic 
disorder. They have been found to be a better predictor of 
long-term outcome than positive symptoms, as they are 
closely related to functional outcomes. However, since 
cognitive deﬁ  cits often “smolder” in the background of more 
expressive positive and negative symptoms and may persist 
even after sufﬁ  cient treatment of acute psychotic episodes, 
they have not received as much clinical attention. This per-
spective seems to change, and some authors have suggested 
expanding the notion of antipsychotic efﬁ  cacy to include 
changes in cognitive function (Velligan et al 2002). 
It has been shown that newer antypsychotics may have 
superior efﬁ  cacy in addressing schizophrenia-associated 
cognitive deﬁ  cits to older agents (Mishara and Goldberg 
2004). A small study (n = 22; n = 10, quetiapine; n = 12, 
controls) reported by Sax et al (1998) compared the effects 
of a 2-month treatment course of medication versus placebo 
and found a signiﬁ  cant improvement in attention span in the 
quetiapine-treated group.
Another small, double-blind, randomized comparative 
trial was published by Purdon et al (2001) on cognitive effects 
of quetiapine (n = 13, 468 ± 114.6 mg/day) and high-dose 
haloperidol treatment (n = 12, 15.5 ± 3.3 mg/day). After a 
6-month observation period, there was a signiﬁ  cant trend 
towards improvement on the general cognitive index for que-
tiapine. Quetiapine also had beneﬁ  cial effects on cognitive 
skills, particularly verbal reasoning and ﬂ  uency skills and 
immediate recall, with additional improvements on execu-
tive skills and visuomotor tracking and on the average of 
the 6 cognitive domains with sustained treatment. Positive, 
negative, and depressive symptoms of schizophrenia also 
improved and quetiapine was the better tolerated medication 
overall. The authors caution, however, that the results may 
not be generalizable, as only very few patients completed the 
entire trial (n = 8, quetiapine; n = 3, haloperidol). 
Velligan et al (2003) compared the effects of 24 weeks of 
treatment with quetiapine (300 and 600 mg) and haloperidol 
(12 mg) in 58 patients. Subsets of cognition including verbal 
ﬂ  uency (p < 0.04), attention (p < 0.03) and verbal memory 
(p < 0.02) improved more robustly with the 600 mg quetiap-
ine dose than either in the 300 mg quetiapine group or 12 
mg haloperidol group.
An interim-analysis of an open-label, 2-year study 
examining the effects of quetiapine on cognition in patients 
with a ﬁ  rst episode of schizophrenia and related disorders was 
conducted by Good et al (2002). One-year data for 13 patients 
was available (mean dose 517.9 ± 225.8 mg). Statistically 
signiﬁ  cant improvements were noted on measures of atten-
tion, verbal ﬂ  uency, and executive function after 6 and 12 
months of treatment. 
In 2 short-term, double-blind, randomized trials con-
ducted by Riedel and colleagues (2007a, b) comparing que-
tiapine with risperidone and olanzapine, all three compounds 
improved cognition; however, the improvement in cognitive 
index scores was more marked in patients receiving quetiap-
ine. Furthermore, quetiapine produced a signiﬁ  cantly greater 
improvement in reaction quality/attention than risperidone 
and olanzapine.
Switching studies
A single, large (n = 509), open-label, naturalistic, indus-
try-supported, multicenter study to examine the efﬁ  cacy 
of quetiapine after a switch from another neuroleptic or 
combinations thereof was conducted by de Nayer et al 
(2003) (SPECTRUM trial). Non-responders and those 
poorly tolerant to the previous antipsychotics were included. 
Quetiapine was efﬁ  cacious overall, in both non-responders 
and non-tolerators, especially with respect to improving 
depressive symptoms. Quetiapine showed, in certain cases, 
marked amelioration of acute EPS induced by the previously Neuropsychiatric Disease and Treatment 2007:3(2) 228
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administered medication. Furthermore these results could 
have been conﬁ  rmed by a recently published post hoc analysis 
of the SPECTRUM trial which was carried out to evaluate 
whether the improvements in efﬁ  cacy and tolerability gained 
on switching to quetiapine occurred consistently for patients 
previously treated with an antipsychotic monotherapy (Larmo 
et al 2005). Switching to quetiapine showed a signiﬁ  cant 
improvement in terms of efﬁ  cacy and tolerability regardless 
of whether their previous antipsychotic was haloperidol, 
olanzapine, or risperidone. Among another chronically ill 
group of schizophrenia patients who had just discontinued 
treatment with an atypical antipsychotic (n = 168), quetiapine 
was moderately effective as measured by discontinuation for 
any reason (Stroup et al 2006). In patients who prospectively 
failed to improve with a variety of newer antipsychotics, 
clozapine may be more effective than switching to another 
newer antipsychotic (McEvoy et al 2006). 
Place in the treatment of dementia-
related behavior
In a 10-week, double-blind, placebo-controlled, multicenter 
trial, Zhong et al (2004) examined the efﬁ  cacy of quetiapine on 
agitated behavior problems in geriatric inpatients with demen-
tia. Patients (n = 333) were randomized to either quetiapine or 
placebo. Dose escalation to 200 mg occurred within 8 days and 
was generally well tolerated. A mean dose of 200 mg quetiap-
ine was signiﬁ  cantly superior to placebo in controlling anxiety 
and improving CGI. During the 10-week treatment duration, 
no cerebrovascular accidents were observed. Similarly, Tariot 
et al (2000) reported on a 52-week, open-label, multicenter trial 
of quetiapine administered to geriatric patients. Quetiapine was 
efﬁ  cacious and safe. Slower uptitration was better tolerated. 
The authors recommended starting treatment at 25 mg and 
increasing slowly up to 100–150 mg.
To further examine cerebrovascular risks of quetiapine, 
Schneider et al (2004) analyzed data from 2 double-blind, 
placebo-controlled, randomized, multicenter trials incorpo-
rating a total of 684 patients (quetiapine n = 355, haloperidol 
n = 116, placebo n = 213). No increased CVA risk in either 
group was found. 
Treatment of borderline personality 
disorder
A pilot study conducted by Bellino et al (2006) suggests that 
quetiapine is efﬁ  cacious and well tolerated in treating patients 
who have borderline personality disorder, particularly when 
impulsivity and aggression-related symptoms were promi-
nent. These results are in line with many clinical observa-
tions of beneﬁ  cial effects of quetiapine in the treatment of 
borderline patients. 
Use in child and adolescent psychiatry
Shaw et al (2001) conducted a 8-week open label study 
incorporating 15 adolescents with diagnosable DSM-IV 
schizophrenia (mean age 15.1 years). A signiﬁ  cant im-
provement under quetiapine treatment was reported. BPRS, 
PANSS, Young-Mania (Young et al 1978), and CGI scale 
scores all showed improvements. Moderate to marked 
weight gain of approximately 4.1 kg was observed. A 
non-signiﬁ  cant reduction in thyroxin (T4) and increased 
thyroid-stimulating hormone (TSH) were seen. Quetiapine 
was well tolerated overall.
A small, 88-week, open-label study McConville et al 
(2003) reported results of quetiapine treatment on long-term 
efﬁ  cacy and tolerability in 7 schizoaffective and 3 bipolar 
adolescents. Signiﬁ  cant improvements in BPRS, CGI, and 
SANS were noted. Neither acute EPS nor tardive dyskinesias 
were observed. Weight gain was nonsigniﬁ  cant.
Delbello et al (2002) conducted a randomized, double-
blind, placebo controlled trial on the efﬁ  cacy of quetiapine 
as adjuvant medication in the treatment of adolescent mania. 
Quetiapine was added to valproate. Thirty adolescents aged 
12–18 years with acute manic or mixed episode in context of 
a DSM-IV bipolar disorder were included; half of the patients 
received either add-on quetiapine or add-on placebo. The 
main outcome parameter was the change in Young Mania 
Rating Scale (YMRS). Quetiapine add-on was associated 
with signiﬁ  cantly better improvement of YMRS scores than 
placebo add-on. The quetiapine-valproate combination was 
well tolerated.
Treatment of bipolar disorder
Two randomized, double-blind, placebo-controlled trials 
looking at efﬁ  cacy and tolerability of quetiapine as add-
on to standard of care in the treatment of acute bipolar 
disorder have been published (Sachs et al 2004; Calabrese 
et al 2005). 
The trial by Sachs et al (2004) was a brief (3-week), mul-
ticenter, add-on study of quetiapine in patients with DSM-IV 
acute bipolar mania (n = 91). Quetiapine (600–800 mg/day) 
or placebo were added to either lithium or valproate medi-
cation. Quetiapine add-on was associated with signiﬁ  cantly 
greater improvement in several areas. More patients receiv-
ing quetiapine showed reduction in mania scores (50% 
YMRS-Score reduction), remission of mania (deﬁ  ned as Neuropsychiatric Disease and Treatment 2007:3(2) 229
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YMRS <12), and improvements in CGI. Mean quetiapine 
dose was 584 mg/day. Somnolence and dry mouth were 
signiﬁ  cantly more commonly associated with quetiapine, 
however did not translate into higher drop-out rates.
In a combined analysis of two 12-week placebo-
controlled trials (n = 403) about quetiapine monotherapy (up 
to 800 mg/day) for mania associated with bipolar disorder, 
Vieta et al (Vieta et al 2005) found a signiﬁ  cant improvement 
in YMRS score observed from Day 4 (p = 0.021) onward in 
the quetiapine group compared with placebo. The treatment 
advantage of quetiapine over placebo continued to increase to 
Day 21 (p < 0.001) and Day 84 (p < 0.001). Of adverse events 
occurring in 5% of patients, quetiapine-treated patients had 
a signiﬁ  cantly greater incidence versus placebo of somno-
lence (16.3% vs 4.0%), dry mouth (15.8% vs 3%), weight 
gain (9.1% vs 1.5%), and dizziness (6.7% vs 2.5%). 
A study of Calabrese et al (2005) indicated good efﬁ  cacy 
of either 300 or 600 mg of quetiapine in the treatment of 
bipolar depression (n = 542). Results from this short-term 
trial (8 weeks) indicated signiﬁ  cantly greater efﬁ  cacy of 
either quetiapine dose than placebo on Montgomery 
Asberg Depression Rating Scale (MADRS) and Hamilton 
Depression Rating Scale (HAM-D) (Hamilton 1960) scores. 
Quetiapine was not associated with induction of mania or 
hypomania. Frequent side-effects were dry mouth, dizziness, 
sedation, and constipation.
Treatment of Parkinson’s patients 
for iatrogenically induced psychotic 
symptoms
Iatrogenically induced psychotic symptoms are a common 
complication in the treatment of Parkinson’s disease.
Morgante et al (2004) conducted a 12-week, randomized, 
open-label, trial of quetiapine versus clozapine in 40 patients 
with Parkinson’s disease who had developed psychotic symp-
toms as a result of their primary treatment. BPRS and Clinical 
Global Impression-Severity Scale (GCI-S) scores were used to 
track changes in psychopathology. Quantiﬁ  cation of potential 
movement disorders was done with the Uniﬁ  ed Parkinson’s 
Disease Rating Scale (UPDRS) III (UPDRS, 2003) and the 
AIMS (Guy 1976). Low-dose quetiapine and clozapine were 
equally efﬁ  cacious per BPRS and CGI changes (p < 0.001); tol-
erability of low-dose quetiapine was good. Neither medication 
worsened symptoms of the primary Parkinson’s disease in 
low doses. However, the authors recommended not exceeding 
100 mg of quetiapine because in higher doses, adverse motor 
symptoms were observed.
Augmentation with quetiapine of patients 
treated with selective serotonin reuptake 
inhibitors (SSRIs)
SSRIs are the mainstay of treatment of depressive and anxiety 
disorders. A small subset of patients, however, continues to 
suffer from anxiety symptoms in the long run.
Adson et al (2004) conducted a small (n = 11), 9-week, 
open-label trial adding quetiapine to pre-existing SSRI 
treatment. HAM-D and HAM-A (Hamilton 1960) and 
State Anxiety Inventory (SAI Ferreira and Murray 1983) 
were used to measure associated psychopathology changes. 
Patients were required to have been pretreated with and 
been only partially responsive to SSRI after at least 6 weeks 
of SSRI exposure. A signiﬁ  cant symptomatic improve-
ment was seen in 10 of the 11 patients; however caution 
should be used in generalizing the results given the small 
sample size.
Tolerability
Overview
Side-effects most commonly associated with quetiapine 
(>10% per clinical trials) are somnolence, dizziness, dry 
mouth, asthenia, constipation, tachycardia, orthostatic 
hypotension, dyspepsia, and weight gain. Furthermore 
weight gain, syncopal episodes, leucopenias, neutropenias, 
and peripheral angioedema are sporadically associated with 
quetiapine treatment.
Mullen et al (2001) published results from the indus-
try-sponsored QUEST study comparing the efﬁ  cacy and 
tolerability of quetiapine with risperidone. The 16-week, 
open-label, multicenter trial (n = 728) revealed that signiﬁ  -
cant proportions of patients receiving quetiapine developed 
somnolence (31.3% vs 15.4% on risperidone), dry mouth 
(14.5% vs 6.9%), and dizziness (12.7% vs 6.9%) (Table 2). 
Overall tolerance to side-effects with the two drugs, measured 
by dropout rates, was comparable. The EPS proﬁ  le was more 
Table 2 Quetiapine side-effect proﬁ  le (Mullen et al 2001)
Side-effecta Quetiapine
 (n  =  553)
Overall 400  (72.3%)
Somnolence 173  (31.3%)
Dry mouth  80 (14.5%)
Dizziness 70  (12.7%)
Insomnia 65  (11.8%)
Headache 52  (9.4%)
Agitation 34  (6.1%)
aside-effects reported with >5% frequency.Neuropsychiatric Disease and Treatment 2007:3(2) 230
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favorable for quetiapine (329 mg/day) than for risperidone 
(5 mg/day).
EPS
Most of the newer agents have better tolerability with re-
spect to acute EPS. Especially older agents, and the newer 
agent aripiprazole have been associated with akathisia; other 
EPS including dyskinesias, dystonias, and parkinsonoid 
have predominantly been observed with the older agents. 
Although long-term data are still scarce, it appears that older 
antipsychotics are associated with higher risks for tardive 
dyskinesias than newer ones, which are therapeutically 
difﬁ  cult to ameliorate. 
Incidence and quantiﬁ  cation of EPS is usually done with 
standard rating scales, including the 
1.  Simpson Angus Scale (SAS; Simpson and Angus 1970), 
a rater-administered 10-item scale to assess medication-
induced Parkinson-like symptoms 
2.  Abnormal Involuntary Movement Scale (AIMS), a 
12-item scale assessing movement disorders including 
akathisia and tardive dyskinesia.
3.  Barnes Akathisia Scale (BAS; Barnes 1989) a 4-item scale 
to quantify medication-induced akathisia symptoms. 
Quetiapine has an overall low risk for inducing EPS 
(Aravantis et al 1997; Simpson and Angus 1970). The 
QUEST study (Mullen et al 2001), a comparative efﬁ  cacy 
and safety trial of quetiapine (n = 553) versus risperidone 
(n = 175), showed equal inital rates for acute EPS of 53% for 
quetiapine and 52% for risperidone. Intensity of acute EPS 
gradually decreased during the 4-month trial period. EPS 
were less severe in quetiapine-treated patients, but remained 
present throughout in both groups. However, antipsychotic 
dose reductions and additional prescription of anticholiner-
gics were signiﬁ  canlty less common in quetiapine-treated 
patients (p < 0.001; Figure 7).
Better tolerability of quetiapine (with respect to induction 
of acute EPS, prolactin elevations, and weight gain) was also 
reported by Riedel et al (2005) in a 12-week comparative 
RCT of quetiapine and risperidone in the treatment of pre-
dominantly negative-symptom schizophrenia (n = 44).
Kasper et al (2004) reported results from a pooled 
analysis of 4 commercially funded, open label, phase IIIa 
extension trials on the long-term efﬁ  cacy and tolerability 
(208 weeks) of quetiapine (n = 674). EPS occurred in 
approximately 9% of patients, predominantly akathisia 
(3.1%), other acute EPS (2.5%), and tremors (1.6%). Three 
patients had to be withdrawn from the protocols secondary 
to serious EPS.
A recent 12-month, double blind, RCT of quetiapine 
versus high-dose haloperidol reported by Emsley et al (2004), 
examined the potential of quetiapine to favorably inﬂ  uence 
pre-existing tardive dyskinesias in schizophrenia patients. 
Fifty-ﬁ  ve patients (quetiapine n = 22; haloperidol, n = 23) 
were examined for changes in tardive dyskinesia sever-
ity via the Extrapyramidal Symptom Rating Scale (ESRS) 
Figure 7 Percentage of patients with extrapyramidal-motor side-effects (EPS) (compiled from data of Mullen et al 2001).
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(Chouinard et al 1980). Compared with the haloperidol-
treated group, quetiapine patients experienced signiﬁ  cant 
improvement in ESRS scores (p < 0.01) leading the authors to 
conclude that quetiapine may have the potential to positively 
inﬂ  uence tardive dyskinesia.
Prolactin
Medication-induced prolactin elevations may induce 
side-effects such as galactorrhoea, gynecomastia, menstrual 
cycle abnormalities, and sexual dysfunctions. They can 
strongly inﬂ  uence medication adherence rates. A short-term 
study (6 weeks) by Atmaca et al (2002) in 35 female schizo-
phrenia patients treated with either quetiapine (n = 18) 
or high-dose haloperidol (n = 17) found a doubling of 
haloperidol-associated prolactin levels (baseline 15.4 ± 4.2 
ng/mL to 31.4 ± 10.2 ng/mL; p < 0.001) whereas quetiapine 
did not change prolactin levels (15.3 ± 4.4 ng/mL to 15.7 
± 4.8 ng/mL). Conversely, Stevens et al (2005) reported 
mild dose-dependent increases in serum prolactin levels 
for quetiapine, but with an insigniﬁ  cant effect of exposure 
time. Results are consistent with previous reports (Hamner 
et al 1996).
Weight gain
Patients are well aware of antipsychotic-induced weight 
gain (Strassnig et al 2005), and experience weight gain 
as an impairment to their overall quality of life (Strassnig 
et al 2003). Importantly, marked weight gain is a predic-
tor for medication nonadherence in schizophrenia patients 
(Perkins, 1999). Available antipsychotics have different 
weight gain liabilities (Sussman, 2001; Brecher et al 2000). 
Compared to other newer antipsychotics, quetiapine treat-
ment induces moderate short-term weight gain (Allison et al 
1999); two 6-week clinical trials reported a mean weight 
gain of 2.08 kg (Jones et al 2000). Similarly, Zhong et al 
(2006) reported mean weight gain of 2.33 kg in a 8-week 
comparative study of quetiapine with risperidone (2.06 kg 
for ris, p = ns). Long-term data are scarce. An analysis of 
pooled data (n = 674 patients) of long-term treatment with 
quetiapine over 208 weeks revealed moderate weight gain 
potential, mostly during the inital 26 weeks of treatment and 
at a lower rate thereafter (compared to baseline, 26th week 
3.2 ± 6.88 kg, 52nd week 3.4 ± 8.6 kg, 208th week 4.9 ± 
11.89 kg). In the CATIE study, Lieberman and colleagues 
found that weight gain in patients treated with quetiap-
ine was similar to risperidone (mean weight change was 
1.1 ± 0.9 and 0.8 ± 0.9 lb, respectively), whereas olanzapine 
was associated with greater weight gain (9.4 ± 0.9 lb) and 
increases in measures of glucose and lipid metabolism 
(Lieberman et al 2005). 
Hyperglycemia, new-onset type II 
diabetes
Glucose intolerance, frank hyperglycemia, new-onset type 
II diabetes, and diabetic ketoacidosis (DKA) are more 
common in patients when they are treated with atypical 
antipsychotics compared with classic agents (Jin et al 2004). 
Concerns about medication-related type II diabetes is par-
ticularly high in schizophrenia patients, as there is evidence 
that patients may be predisposed and more susceptible to 
developing the insulin resistance syndrome (Mukherjee 
et al 1996). Biological and retrospective studies generally 
ﬁ  nd abnormal glucose tolerance during extended treatment 
(Jin et al 2004). 
Quetiapine seems to occupy a “middle-ground” among 
newer antipsychotics with respect to its propensity to induce 
hyperglycemia/diabetes type II. Leslie and Rosenheck (2004) 
analyzed the VA Connecticut Mental Health prescription 
database for new-onset diabetes secondary to antipsychotic 
administration. 4132 (7.3%) of patients had developed dia-
betes mellitus and among these, 88 (0.2 %) required inpatient 
hospitalization for ketoacidosis. The relative risk for new 
onset diabetes under quetiapine treatment was not different 
to that with risperidone and conventional antipsychotics, 
and lower than with either olanzapine or clozapine. The 
authors conclude that the absolute risk for development of 
diabetes secondary to treatment with atypical antipsychotics 
is relatively low (lowest for risperidone 0.05%, highest for 
clozapine 2.03%). 
Gianfrancesco et al (2003) analyzed a large health 
insurance database for new-onset diabetes in schizophrenia 
patients treated with newer antipsychotics. Among 922 
patients receiving quetiapine, 117 developed new-onset 
diabetes. Odds ratios were extrapolated for 12-month 
exposure, and were signiﬁ  cantly elevated only for olan-
zapine, but not for risperidone, quetiapine, or conventional 
antipsychotics. 
In a recently published review article Chu and Cheung 
(2006) concluded that an increased risk of diabetes with 
some atypical antipsychotics should not deter physicians 
from using these agents in patients with schizophrenia or 
bipolar disorder, but they recommended that antipsychotic 
therapy should be carefully selected in those patients at 
greatest risk of developing diabetes or metabolic syn-
drome. Appropriate management and regular monitoring 
of patients receiving antipsychotics should minimize the Neuropsychiatric Disease and Treatment 2007:3(2) 232
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risk of patients with schizophrenia or bipolar disorder 
developing diabetes.
Hematological and blood chemistry 
changes
While much of the literature has focused on weight gain 
and glucose intolerance, the importance of recognizing and 
treating hyperlipidemia in schizophrenia patients cannot be 
overemphasized (Meyer and Koro 2004). Data are scarce on 
quetiapine. The available data suggest that quetiapine shares 
the propensity with other benzodiazepine-derived atypical 
antipsychotics to primarily elevate serum triglycerides, and to 
a lesser extent cholesterol levels (Meyer and Koro 2004). 
Potkin et al (2006) reported increased risk for thyroid 
dysregulation in quetiapine-treated inpatients; however, 
changes in thyroid hormones occurred mainly during an 
additive therapy phase with other antipsychotics in this study. 
Changes were reversible with treatment cessation. TSH 
increased signiﬁ  cantly in 0.4 % of patients. Clinically relevant 
hypothyreosis was not observed in the majority of patients. 
Goldstein (1999) described transient, clinically asymp-
tomatic liver enzyme elevations, predominantly alanine 
transaminase (ALT) during quetiapine treatment. Most 
increases appeared within 3 weeks of treatment initiation, 
and subsequently subsided.
No cases of persistent clincially signiﬁ  cant neutropenia 
or agranulocytosis have been reported. Previous experience 
shows that neutropenia and leukopenia induded by quetiapine 
were reversible after removal of the drug. Risk factors are a 
history of medication-induced neutropenia and pre-existent 
low white blood count. 
Cardiovascular system
Reilly et al (2000) reported increased risks for QTc prolon-
gation effected by several antipsychotics including thio-
ridazine, droperidol, and ziprasidone. Prolongation of the 
QT interval (determined by ECG) and the QTc – corrected 
for heart rate – may lead to serious cardiac arrhythmias and 
sudden death. 
A review by Goldstein (1999) on quetiapine-induced 
ECG changes showed a small QTc time prolongation with 
quetiapine independent of quetiapine plasma levels.
The incidence of QTc time prolongation and associated 
risk for torsades de pointes arrhythmia and ensuing car-
diac arrest was examined by Glassman and Bigger (2001). 
Haloperidol, pimozide, sertindole, and droperidol all showed 
increased risk for torsades de pointes arrhythmia; the highest 
risk was associated with thiroidazine. No association with 
olanzapine, quetiapine, or risperidone was found. Among the 
newer agents, only ziprasidone prolonged QTc time. 
A review by von Vieweg (2003) on the association of 
newer antipsychotics and QTc time prolongation concluded 
that up to 2002 there was no convincing evidence for 
involvement of these agents in triggering torsades de pointes 
arrhythmia; but non-emergence of QTc time prolongation 
could not safely be excluded either. Still, based on available 
evidence, the reviewer argued that no special precautions 
are necessary in patients without pre-existing risk for ECG 
changes started on newer medications. 
However, according to the CATIE trial the mean change 
in QTc interval from baseline to last observation was 5.9 ± 
1.9 ms in quetiapine-treated patients in comparison with 
other atypicals (risperidone 0.2 ± 1.8 ms; olanzapine 1.2 ± 
1.8 ms; ziprasidone 1.3 ± 2.2 ms; and perphenazine 1.4 ± 
2.0 ms) (Lieberman et al 2005).
In a randomized evaluation of the effects of 6 antipsy-
chotic agents (haloperidol 15 mg/d [n = 27], thioridazine 
300 mg/d [n  =  30], ziprasidone 160 mg/d [n = 31], que-
tiapine 750 mg/d [n = 27], olanzapine 20 mg/d [n  =  24], 
or risperidone 6–8 mg/d increased to 16 mg/d [n  =  25/20]) 
on the QTc time, Harrigan et al (2004) found that mean 
QTc intervals did not exceed 500 ms in any patient taking 
any of the antipsychotics studied, a threshold generally 
accepted as being clinically important for the association 
with the development of torsades de pointes (Bednar et al 
2001). The authors concluded that the theoretical risk of 
cardiotoxicity associated with QTc prolongation should be 
balanced against the substantial clinical beneﬁ  ts associated 
with atypical antipsychotics and the likelihood of other 
toxicities.
Conclusion
Efﬁ  cacy of quetiapine in reduction of positive and negative 
schizophrenia symptoms has been shown in several short- to 
intermediate-term comparative trials and double-blind RCTs. 
Long-term efﬁ  cacy on a variety of symptoms has also been 
established. Cognitive, depressive, and aggressive symp-
toms in the context of schizophrenia have been successfully 
treated. Other indications, such as treatment of moderate 
to severe manic episodes, treatment of aggressive behavior 
in children and adolescents, and behavioral disturbances in 
patients with dementia, have also been explored and have 
been successfully carried out. More recent data point to good 
efﬁ  cacy of quetiapine in the treatment of depressive episodes 
in the context of bipolar disorder, while lacking the potential 
to trigger switch into mania. Borderline personality disorder Neuropsychiatric Disease and Treatment 2007:3(2) 233
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is another diagnostic category in which quetiapine has suc-
cessfully been applied, although results are preliminary. 
Quetiapine’s preferred dose ranges from 150 to 750 mg 
daily; yet clinical trials indicate that – individually and accord-
ing to clinical presentation – a far higher target dose (>1000 
mg daily) may be used. For relapse-prevention, a dose of at 
least 400 mg/day should be prescribed. Switching to quetiapine 
secondary to lack of efﬁ  cacy or tolerability of the previous drug 
may be effective and is usually well tolerated. 
The most prominent side-effects associated with que-
tiapine treatment are somnolence, dizziness, dry mouth, 
asthenia, constipation, tachycardia, orthostatic hypotension, 
and dyspepsia (10% in placebo-controlled trials). The ma-
jority of clinical trials emphasize the favorable tolerability 
of quetiapine with regards to extrapyramidal symptoms and 
only mild prolactin elevation. Among newer antipsychot-
ics, quetiapine occupies a middle ground with respect to 
its weight gain potential and liability to induce metabolic 
side-effects such as hyperglycemia and hyperlipidemia. QTc 
prolongation is usually not of clinical signiﬁ  cance.
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